Hybrid Closed-Loop for Diabetes After Kidney Transplant
Part of Hormones & metabolism, Kidney & urinary clinical trials.
This trial tests a hybrid closed-loop system (an advanced insulin pump that automatically adjusts insulin) for people with diabetes who have had a kidney transplant. It may help improve blood sugar control and reduce the burden of managing diabetes after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have diabetes (Type 1 or Type 2) diagnosed by standard criteria.
- You have had a kidney transplant.
- You can learn to use an insulin pump and a continuous glucose monitor (CGM).
- You do not have conditions that would make the pump unsafe for you, like recent severe diabetic emergencies, active skin infections at the pump site, or serious uncontrolled medical problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a hybrid closed-loop insulin pump system for people with LADA (a slow-progressing form of autoimmune diabetes). It aims to see if the system can improve blood sugar control and reduce hypoglycemia.
This trial tests a smart insulin pump (hybrid closed-loop system) to control high blood sugar after brain surgery for bleeding strokes. It's for people with type 2 diabetes who are stable enough to leave the intensive care unit and are getting tube feedings.
This study tests whether a special type of insulin delivery system (closed-loop) can help people with type 2 diabetes and chronic kidney disease. You'll wear a continuous glucose monitor and insulin pump, and researchers will track how your kidneys respond over time.
This trial tests a smart insulin pump system (hybrid closed-loop) to control blood sugar in people with type 2 diabetes who need surgery and will receive nutrition through a vein. It aims to prevent high and low blood sugar during and after surgery.
This trial tests two diabetes medications, empagliflozin and linagliptin, to see which one works better for controlling blood sugar, protecting kidney function, and improving body composition in people who have had a kidney transplant and have diabetes.
This trial tests whether transplanting insulin-producing “islet” cells can better control blood sugar in people who have already received a kidney transplant. It’s mainly for adults with type 1 diabetes whose body is no longer making enough insulin, while they are on kidney-transplant medicines.
Hear when a new Diabetes Mellitus Patients With Kidney Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.